Australia's Amplia Therapeutics jumps on upbeat trial results for pancreatic cancer drug
** Shares of Amplia Therapeutics ATX.AX rise as much as
16.3% to A$0.100, posting their biggest percentage gain since
Oct. 10
** Stock hits its highest level since Nov. 15
** Drug developer reports positive clinical trial results
for its pancreatic cancer drug narmafotinib
** Says 35% patients show partial response in trial vs 23%
in historical standard-of-care treatment
** About 6.4 mln shares change hands, compared with the
30-day average volume of around 1.6 mln
** Stock up 20.7% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement